Evidence map›Paper›PMID 32671942›Full record

ArticleJournal of viral hepatitis2020

Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland.

Risha Irvin, Boatemaa Ntiri-Reid, Mary Kleinman, Tracy Agee, Jeffrey Hitt, Onyeka Anaedozie, Tolu Arowolo, Hope Cassidy-Stewart, CaSaundra Bush, Lucy E Wilson and 9 more

Abstract read
In one paragraph

Article in Journal of viral hepatitis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Hepatitis C Cascades: Data to Inform Hepatitis C Elimination in the United States.Public health reports (Washington, D.C. : 1974) · 2023
    Review
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Risha IrvinDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-5953-9316
Boatemaa Ntiri-ReidInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
Mary KleinmanInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
Tracy AgeeDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jeffrey HittInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
Onyeka AnaedozieInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
Tolu ArowoloInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
Hope Cassidy-StewartInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
CaSaundra BushInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
Lucy E WilsonInfectious Disease Prevention and Health Services Bureau, Maryland Department of Health, Baltimore, MD, USA.
Alexander J MillmanDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0001-5231-1351
Noele P NelsonDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0001-9831-0717
Lauren CanaryDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Sherilyn BrinkleyDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Juhi MoonDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Oluwaseun Falade-NwuliaDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2321-2295
Mark S SulkowskiDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2145-6352
David L ThomasDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0749-925X
Michael T MeliaDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0147-3446

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
HIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0M
Intramural CDC HHS CC999999National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention CDC-RFA-PS14-1413National Institute of Allergy and Infectious Diseases P30AI094189NIAID NIH HHS P30 AI094189NIDA NIH HHS R37 DA013806
6 · The paper itself

Abstract

In 2014, trained healthcare provider capacity was insufficient to deliver care to an estimated 70 000 persons in Maryland with chronic hepatitis C virus (HCV) infection. The goal of Maryland Community Based Programs to Test and Cure Hepatitis C, a public health implementation project, was to improve HCV treatment access by expanding the workforce. Sharing the Cure (STC) was a package of services deployed 10/1/14-9/30/18 that included enhanced information technology and public health infrastructure, primary care provider training and practice transformation. Nine primary care sites enrolled. HCV clinical outcomes were documented among individuals who presented for care at sites and met criteria for HCV testing including risk factor or birth cohort (born between 1945 and 1965) based testing. Fifty-three providers completed the STC training. STC providers identified 3237 HCV antibody-positive patients of which 2624 (81%) were RNA+. Of those HCV RNA+, 1739 (66%) were staged, 932 (36%) were prescribed treatment, 838 (32%) started treatment, 721 (27%) completed treatment and 543 (21%) achieved cure. Among 1739 patients staged, 693 (40%) patients had a liver fibrosis assessment score < F2, rendering them ineligible for treatment under Maryland Medicaid guidelines. HCV RNA testing among HCV antibody-positive people increased from 40% (baseline) to 95% among STC providers. Of 554 patients with virologic data reported, 543 (98%) achieved cure. Primary care practices can effectively serve as HCV treatment centers to expand treatment access. However, criteria by insurance providers in Maryland were a major barrier to treatment.

Indexed as

Hepatitis CHepatitis C, ChronicContinuity of Patient CareHepacivirusHumansMarylandPrimary Health CarePublic Healthhepatitis chepatitis c care continuumprovider task shiftingpublic healthvideo conference training

Identifiers

PMID32671942
PMCPMC7721959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.